ImmuPharma (LON:IMM) Stock Price Up 9.3% – Should You Buy?

ImmuPharma plc (LON:IMMGet Free Report)’s stock price rose 9.3% on Friday . The company traded as high as GBX 4.50 ($0.06) and last traded at GBX 3.94 ($0.05). Approximately 31,560,066 shares were traded during trading, an increase of 60% from the average daily volume of 19,683,289 shares. The stock had previously closed at GBX 3.60 ($0.04).

ImmuPharma Stock Up 9.3 %

The stock has a market cap of £16.39 million, a price-to-earnings ratio of -393.60 and a beta of 1.53. The company has a 50 day simple moving average of GBX 1.75 and a 200 day simple moving average of GBX 1.73.

About ImmuPharma

(Get Free Report)

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Featured Articles

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.